Get the Stockscreener App
2.22
1.99%
-0.04
Adverum Biotechnologies Inc stock is traded at $2.22, with a volume of 140.65K.
It is down -1.99% in the last 24 hours and down -32.06% over the past month.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$2.26
Open:
$2.24
24h Volume:
140.65K
Relative Volume:
0.43
Market Cap:
$46.38M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
-0.3694
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
+0.23%
1M Performance:
-32.06%
6M Performance:
-66.64%
1Y Performance:
-71.64%
1-Day Range:
$2.15
$2.29
1-Week Range:
$2.15
$2.3251
52-Week Range:
$1.78
$10.14
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
2.22 | 46.59M | 0 | -94.11M | -86.06M | -6.01 |
|
ONC
Beone Medicines Ltd Adr
|
246.64 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.63 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.57 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.51 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks
Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus
Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus
RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider
Adverum (ADVM) Projects Funding Through Late 2025 | ADVM Stock N - GuruFocus
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - The Manila Times
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline ... - Bluefield Daily Telegraph
Revolutionary One-Time Gene Therapy Shows 3.5-Year Vision Protection in Wet AMD Patients - Stock Titan
Adverum Biotechnologies Inc (ADVM)’s Market Momentum: Closing Strong at 3.23, Down -10.03 - DWinneX
Adverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal year - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire
Adverum Biotechnologies' SWOT analysis: gene therapy firm faces pivotal year - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum ... - Bluefield Daily Telegraph
Adverum Biotechnologies Inc expected to post a loss of $1.94 a shareEarnings Preview - TradingView
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotechnologies Awards Strategic Stock Options Worth $108,000 to Expand Team - Stock Titan
It makes sense and dollars to buy Adverum Biotechnologies Inc (ADVM) stock - Sete News
Adverum Biotechnologies Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Adverum Biotechnologies Inc [ADVM] Investment Guide: What You Need to Know - knoxdaily.com
Should investors be concerned about Adverum Biotechnologies Inc (ADVM)? - uspostnews.com
Gaining Ground: Adverum Biotechnologies Inc (ADVM) Closes Lower at 2.91, Down -2.02 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and - Insider Monkey
Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing - marketscreener.com
Adverum Biotechnologies Insider Buys 350,000 Shares - TradingView
Adverum Biotechnologies Inc (ADVM) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at 2.96, a 8.42 Surge/Plunge - DWinneX
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Chardan Capital Cuts Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $33.00 - American Banking and Market News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com
Adverum Biotechnologies (NASDAQ:ADVM) Earns Buy Rating from HC Wainwright - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect - markets.businessinsider.com
RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress - TipRanks
Adverum Biotechnologies: Q4 Earnings Snapshot - CT Insider
Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adverum Biotechnologies Inc Stock (ADVM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER |
May 15 '25 |
Sale |
2.00 |
924 |
1,848 |
13,768 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR |
May 15 '25 |
Sale |
2.00 |
9,126 |
18,252 |
87,488 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 27 '25 |
Buy |
5.19 |
16,593 |
86,089 |
141,800 |
| Leonard Braden Michael | 10% Owner |
Apr 22 '25 |
Buy |
3.00 |
300,000 |
900,000 |
3,057,526 |
| Leonard Braden Michael | 10% Owner |
Apr 23 '25 |
Buy |
2.98 |
50,000 |
148,950 |
191,800 |
| Leonard Braden Michael | 10% Owner |
Mar 31 '25 |
Buy |
4.38 |
19,566 |
85,668 |
2,742,317 |
| Leonard Braden Michael | 10% Owner |
Apr 02 '25 |
Buy |
4.04 |
15,209 |
61,408 |
2,757,526 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 18 '25 |
Buy |
4.69 |
62,341 |
292,418 |
2,667,161 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):